Home > Insider Trading > Filing (0001209191-20-065499)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1253689	Glycomimetics Inc	GLYC	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1589712	K. Rachel King	C/O Glycomimetics, Inc. 9708 Medical Center Drive Rockville MD 20850	President, Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-12-28	130,821	$1.12	440,240	No	4	M	Direct
Common Stock	Disposition	2020-12-28	84,176	$3.91	356,064	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (right to buy)	Disposition	2020-12-28	130,821	$0.00	130,821	$1.12

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2021-01-04	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	129,401	Indirect	By trusts
Common Stock	45,741	Indirect	By spouse

Footnotes

This option exercise and subsequent sales were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on August 4, 2020.
This total includes 2,275 shares previously held by The Rachel K. King 2016 GRAT that were transferred to the Reporting Person on January 10, 2020 and are now owned directly by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.85 to $4.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
This total excludes the 2,275 shares transferred to the Reporting Person as described in footnote (2) above.
These shares are held by family trusts, for which Ms. King serves as trustee, as follows: 1,741 shares are held by The Connor A. King 1988 Trust, 1,741 shares are held by The Langley C. King 1990 Trust, 8,796 shares are held by the 1995 Connor A. King Trust, 8,796 shares are held by the 1995 Langley C. King Trust, 23,301 shares are held by The Connor King 2013 GRAT, 23,301 shares are held by The Langley C. King 2013 GRAT and 61,725 shares are held by The Rachel K. King 2016 GRAT.
The shares underlying this option are fully vested and exercisable.